Blastomycosis Case Report Form	
Unique patient ID (State initials + unique state ID):	
NNDSS State ID:	_ □ Not applicable
NORS ID:	_ □ Not applicable
EIP laboratory ID:	_ □ Not applicable
Form completion data	
Name of person completing this form:	yyyy) (mm-dd-yyyy) (mm-dd-yyyy) n-dd-yyyy)
*This is the date of specimen collection for the patient's first positive blastomy	cosis test
A. Case Surveillance Information	
Reporting state/jurisdiction:	
Reporting county:	
Case classification status: ☐ Confirmed ☐ Probable ☐ Suspect ☐ Not a case ☐ Unl	known

## **CHART REVIEW**

B. Patient Demographics	
1. Age at DISC:	
(use months or days if patient was aged <2 years)	□ Years □ Months □ Days □ Unknown
2. Sex	□ Male □ Female
3. What is your race and/or ethnicity? (select all that apply and enter additional details in the spaces provided)	□ American Indian or Alaska Native Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, etc. □ Asian - provide details below □ Chinese □ Asian Indian □ Filipino □ Vietnamese □ Korean □ Japanese Enter, for example, Pakistani, Hmong, Afghan, etc. □ Black or African American - provide details below

	□ African American □ Jamaican □ Haitian □ Nigerian □ Ethiopian □ Somali Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc. ————				
	☐ Hispanic or Latino – provide details below ☐ Mexican ☐ Puerto Rican ☐ Salvadoran ☐ Cuban ☐ Dominican ☐ Guatemalan Enter, for example, Colombian, Honduran, Spaniard, etc.				
	□ Middle Eastern or North African – provide details below □ Lebanese □ Iranian □ Egyptian □ Syrian □ Iraqi □ Israeli Enter, for example, Moroccan, Yemeni, Kurdish, etc.				
	□ Native Hawaiian or Pacific Islander – provide details below □ Native Hawaiian □ Samoan □ Chamorro □ Tongan □ Fijian □ Marshallese Enter, for example, Chuukese, Palauan, Tahitian, etc.				
	□ White – provide details below □ English □ German □ Irish □ Italian □ Polish □ Scottish Enter, for example, French, Swedish, Norwegian, etc. ————————————————————————————————————				
4. Patient's country of primary residence (e.g., USA)	□ Unknown				
5. Patient's state, jurisdiction, or territory of primary residence	□ Unknown				
6. Patient's county of primary residence (Please do not write the word "County"; for example, write "Cook" instead of "Cook County"):	□ Unknown				
7. Patient's city of primary residence	□ Unknown				
8. Patient's ZIP code of primary residence	□ Unknown				
9. Patient's type of health insurance at DISC	□ Private □ Medicare □ Medicaid/state assistance program □ Military □ Indian Health Service □ Incarcerated □ Uninsured □ Other (specify): □ Unknown				
C. Patient underlying risk factors & medical condition	ons present during the 2 years before DISC (unless other timeframe specified)				
1. Cancer  ☐ Yes  ☐ No  ☐ Unknown	2. HIV infection □ Yes □ No □ Unknown				
□ Hematologic malignancy	If yes, choose one of the below				
specify malignancy:	Ever had CD4 < 200 cells/mm³ within past 6 months				
□ Solid organ malignancy	□ Yes □ No □ Unknown				
specify organ:					
□ Chemotherapy					

CDC estimates the average public reporting burden for this collection of information as 60 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

4. Any respiratory viral test in 120 days before or after DISC

☐ Chronic obstructive pulmonary disease (COPD) or emphys	ema 🛮 Yes 🗷 No 🗆 Unknown
□ Bronchiectasis	
□ Cystic fibrosis	If yes, (select all that apply):
☐ Allergic bronchopulmonary aspergillosis (ABPA)	☐ SARS-CoV-2 (PCR or antigen test)
□ Pulmonary fibrosis	Date of specimen collection (mm/dd/yyyy):
□ Asthma	□ Positive □ Negative □ Unknown
□ Interstitial Lung Disease	□ Influenza
□ Other chronic pulmonary diagnosis (specify):	Date of specimen collection (mm/dd/yyyy):
	☐ Positive ☐ Negative ☐ Unknown☐ Other respiratory virus (specify)
	Date of specimen collection (mm/dd/yyyy):
	□ Positive □ Negative □ Unknown
5. Transplant received within 2 years before DISC	6. Other selected conditions:
□ Yes □ No □ Unknown	□ None
	□ Cardiovascular disease
□ Solid organ transplant:	(specify):
□ Lung □ Heart □ Kidney □ Pancreas □ Liver □ Skin graf	t □ Diabetes mellitus
□Other: □ Unknown	□ End stage renal disease/dialysis
	☐ Autoimmune disease(s) or inherited immunodeficiency(-ies)
☐ Hematopoietic stem cell transplant (HSCT)	(specify):
	☐ Medications/therapies that weaken the immune system
	☐ TNF-alpha inhibitors (e.g., infliximab, adalimumab, etanercept)
	□ Other (specify):
	□ Cirrhosis
	☐ Liver disease without cirrhosis
	□ Systemic lupus erythematosus
	☐ Systemic Tupus et ythematosus
	☐ Pregnant☐ Pregnant on DISC☐
	Gestational age (weeks): Unknown
	□ Post-partum (gave birth within 6 weeks before DISC)
7. Please list any other notentially relevant clinical information:	Bartum (gave birth within 0 weeks before Disc)
D. Social History	
1. Smoking (select all that apply)	. current □ Tobacco, previous □ F-nicotine delivery system, current □ F-nicotine

CDC estimates the average public reporting burden for this collection of information as 60 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

delivery system, previous  $\square$  None  $\square$  Unknown

☐ Yes, with documented use disorder☐ Yes, without documented use disorder

☐ Yes, specify other illicit substance(s):

□ No □ Unknown

☐ Yes ☐ No ☐ Unknown

□ No
□ Unknown

2. Documented alcohol use disorder

4. Other illicit substance use

3. Cannabis use

E. Laboratory data (specimen and testing data)					
1. Specimen collection date:/_	/				
2. Location of specimen collection:					
<ul><li>☐ Hospital inpatient</li><li>☐ Intensive care unit</li><li>☐ Surgery/OR</li><li>☐ Radiology</li></ul>	□ Outpatient □ Emergency room □ Clinic/Provider's office □ Dialysis center	<ul><li>□ Long-term care facility (LTCF)</li><li>□ Long-term acute care hospital (LTACH)</li><li>□ Autopsy</li><li>□ Other</li></ul>			
□ Other inpatient ————	□ Surgery □ Urgent care □ Observational/clinical decision unit □ Other outpatient	□ Unknown			
Antigen					
□ Serum	Result:  □ Pos., titer: □ Neg. □ Unclear □ Unk.  Below limit of quantification?	Laboratory:  □ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ Urine	□ Yes □ No □ Unk. □ Pos., titer: □ Neg. □ Unclear □ Unk. Below limit of quantification? □ Yes □ No □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
Serology	1103 1110 1 01111				
□ Serum □ ID IgG	Result: □ Pos., titer: □ □ Neg. □ Unclear □ Unk.	Laboratory where testing was performed:  □ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp			
□ ID IgM	□ Pos., titer: □ Neg. □ Unclear □ Unk.	□ Other □ Unk. □ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ CF IgG	□ Pos., titer: □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ EIA IgG	□ Pos. □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ EIA IgM	□ Pos. □ Neg. □ Unclear □ Unk. □ Pos. □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk. □ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp			
□ Other:	□ Pos. □ Neg. □ Unclear □ Unk.	□ Other □ MiraVista □ Mayo □ Quest □ LabCorp			
□ Unknown	Ç	□ Other □ Unk.			
□ CSF □ ID IgG	□ Pos., titer: □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
	□ Pos., titer: □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Unk.			
□ ID IgM	□ Pos., titer: □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ CF IgG	□ Pos. □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ EIA IgG	□ Pos. □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			
□ EIA IgM	□ Pos. □ Neg. □ Unclear □ Unk.	□ ARUP □ MiraVista □ Mayo □ Quest □ LabCorp □ Other □ Unk.			

□ Other:	□ Pos.	□ Neg.	□ Unclear	□ Unk.	□ ARUP	□ MiraVista	□ Mayo	□ Quest	□ LabCorp
					□ Other_			Unk.	
□ Unknown									

Other laboratory methods	
□ Bronchial specimen	Result:
□ Culture	□ Pos. □ Neg. □ Unclear □ Unk.
	□ B. dermatitidis □ B. gilchristii □ B. helicus □ Pending □ Unknown
□ Direct smear/cytology	□ Pos. □ Neg. □ Unclear □ Unk.
□ Molecular test (e.g., PCR)	□ Pos. □ Neg. □ Unclear □ Unk.
Specify test:	
□ Other	□ Pos. □ Neg. □ Unclear □ Unk.
□ Unknown	□ Pos. □ Neg. □ Unclear □ Unk.
□ Sputum	Result:
Culture	□ Pos. □ Neg. □ Unclear □ Unk.
	□ B. dermatitidis □ B. gilchristii □ B. helicus □ Pending □ Unknown
□ Direct smear/cytology	□ Pos. □ Neg. □ Unclear □ Unk.
□ Molecular test (e.g., PCR)	□ Pos. □ Neg. □ Unclear □ Unk.
Specify test:	
□ Other	□ Pos. □ Neg. □ Unclear □ Unk.
□ Unknown	□ Pos. □ Neg. □ Unclear □ Unk.
□ Urine	Result:
Culture	□ Pos. □ Neg. □ Unclear □ Unk.
	□ B. dermatitidis □ B. gilchristii □ B. helicus □ Pending □ Unknown
□ Other	□ Pos. □ Neg. □ Unclear □ Unk.
□ Unknown	□ Pos. □ Neg. □ Unclear □ Unk.
□ Lung tissue	Result:
□ Culture	□ Pos. □ Neg. □ Unclear □ Unk.
2 carcare	□ B. dermatitidis □ B. gilchristii □ B. helicus □ Pending □ Unknown
= Historythology	□ Pos. □ Neg. □ Unclear □ Unk.
☐ Histopathology ☐ Molecular test (e.g., PCR)	□ Pos. □ Neg. □ Unclear □ Unk.
Specify test:	Tree Trees Terrores Terror
□ Other	□ Pos. □ Neg. □ Unclear □ Unk.
□ Hpkpowp	□ Pos. □ Neg. □ Unclear □ Unk.
□ Other specimen	Result:
□ Culture	□ Pos. □ Neg. □ Unclear □ Unk.
Culture	□ B. dermatitidis □ B. gilchristii □ B. helicus □ Pending □ Unknown
	□ Pos. □ Neg. □ Unclear □ Unk.
☐ Histopathology	□ Pos. □ Neg. □ Unclear □ Unk.
□ Direct smear/cytology	□ Pos. □ Neg. □ Unclear □ Unk.
□ Molecular test (e.g., PCR)	2.55. 2.556. 2.516.64. 2.516.
Specify test:	□ Pos. □ Neg. □ Unclear □ Unk.
	□ Pos. □ Neg. □ Unclear □ Unk.
□ Unknown	

F. Antifungal susceptibility testing						
Date of culture (mm/dd/yyyy)	Species	Drug	MIC			
_		Amphotericin B				
		Anidulafungin (Eraxis)				
		Caspofungin (Cancidas)				
	□ B. dermatitidis	Fluconazole (Diflucan)				
	□ B. gilchristii □ B. helicus □ Unknown	Flucytosine (5FC)				
		Ibrexafungerp				
		(Brexafemme)				
		Isavuconazole (Cresemba)				
		Itraconazole (Sporanox)				
		Micafungin (Mycamine)				
		Posaconazole (Noxafil)				
		Voriconazole (Vfend)				

G. Patient symptoms, diagnosis, and outcomes					
1. Acute signs/symptoms on or within 60 days before DISC?	☐ Yes ☐ No acute signs or symptoms ☐ Unknown				
1a. Symptoms experienced on or within 60 days before DISC (select all that apply).	Pulmonary: □ Cough □ Hemoptysis □ Wheezing □ Shortness of Breath				
	Other respiratory infection symptoms: □ Sore throat □ Chest pain □ Chills □ Night				
	Sweats   Fever   Fatigue   Stiff neck   Headache   Joint or bone pain or body aches				
	□ Weight loss without trying □ Muscle pain □ Nausea □ Vomiting				
	<b>Dermal:</b> □ Rash or other skin problems ((□ Erythema nodosum □ Erythema				
	multiforme   Other (specify)))				
	Neurologic: □ Confusion □ Seizures				
	Radiologic findings: □ Abnormal findings on chest imaging (e.g., pulmonary infiltrates, cavitation, nodules, or lesions) □ Peripheral lymphadenopathy □ Bone or				
	joint abnormality (e.g., osteomyelitis, pathologic fracture)   Meningitis, encephalitis,				
	or focal brain lesion □ Abscess, granuloma, or lesion in other system				
	□ No acute signs/symptoms				
	□ Other (specify)				
2. Date of earliest symptom onset?	/(mm/dd/yyyy)				
	☐ If exact date unknown, approximate date of onset:				
	□ No acute signs/symptoms				
	□ Unknown				
3. Was the patient part of an outbreak of suspected fungal infections?	□ Yes □ No □ Unknown				
4. Did the patient request to be tested for blastomycosis?	□ Yes □ No □ Unknown				

5. According to treating clinicians, which clinical syndrome(s)	□ Acute pulmonary blastomycosis
related to Blastomyces did the patient have on or within 60	□ Chronic pulmonary blastomycosis
days after DISC?	☐ Acute respiratory distress syndrome (ARDS)
	□ Cutaneous blastomycosis
	□ Blastomycosis meningitis
	Treated with a ventriculoperitoneal (VP) shunt? ☐ Yes ☐ No ☐ Unknown
	□ Focal blastomycosis (specify site):
	Unknown
6. What other clinical diagnoses did the patient have on or	□ Coccidioidomycosis
within 60 days before DISC? (select all that apply)	□ Cryptococcosis
Within 66 days before bise. (select all that apply)	☐ Histoplasmosis
	□ Other fungal infection (specify):
	□ Community-acquired pneumonia
	□ Bacterial pneumonia
	□ Viral pneumonia
	□ Cancer
	□ Tuberculosis
	□ Influenza
	□ COVID-19
	□ Other infection/disease not listed (specify):
	□ None
	□ Unknown
7. Site of Blastomyces infection based on clinical impression	□ Lung □ Skin □ Bone □ Joint □ Central nervous system □ No site identified
on or within 60 days after DISC (select all that apply)	□ Other (specify) □ Unknown
8. Was the patient hospitalized at an acute care hospital in	□ Yes □ No □ Unknown
the 60 days before to 60 days after DISC?	If yes, dates of admission of hospitalization most proximal to DISC,
	Admission date:/(mm/dd/yyyy)
	Discharge date:/ (mm/dd/yyyy)   Still hospitalized
	If yes,
	Received ICU-level care in the 14 days <i>before</i> DISC?: ☐ Yes ☐ No ☐ Unknown
	Received ICU-level care in the 14 days after DISC?: ☐ Yes ☐ No ☐ Unknown
	Discharge ICD-10 diagnosis code(s):
9. Died within 60 days after DISC?	□No
	□ Yes, date of death// (mm/dd/yyyy)
	Cause(s) of death
	If yes, did death occur in hospital? □ yes □ no □ unknown
	II yes, did death occur iii nospital: 🗆 yes 🗆 no 🗅 dilknown
	□ Unknown
10. Did the patient have any outpatient, urgent care, and/or	
emergency department visits in the 60 days before to 60 days	If yes, how many visits? (if more than one, fill out information
after DISC?	below for each visit)
	Date of visit:/(mm/dd/yyyy)
	If date of visit is after DISC, was the visit related to blastomycosis?
	□ Yes □ No □ Unknown

			Setting: ☐ Primary care ☐ Urgent care ☐	□ Emergency department □ Specialty		
		care: Pulmonology □ Specialty care: Infectious Disease □ Other (speci				
		Chief complaint:   Not listed  Unknown				
			Was blastomycosis noted as a possible	diagnosis?		
			□ Yes □ No □ Unknown			
			Did the visit involve fever or recent ons ☐ Yes ☐ No ☐ Unknown	set of respiratory symptoms:		
			L TES L NO L OTIKIOWIT			
11. Was a chest x-ray taken within 60 days b	efore to 60 days	п Yes п I	lo □ Unknown			
after DISC?			If yes, were any of the chest x-rays abn	normal □ Yes □ No □ Unknown		
			Date of first abnormal chest x-ray:			
			(mm/dd/yyyy)			
			For first abnormal chest x-ray, select al	ll that apply;		
			□ Air space density □ Air spa	ce opacity □ Consolidation □ Cavitary		
				onary infiltrate □ Interstitial infiltrate		
				Report not available   Other		
			(specify):	Unknown		
40.14	1 ( ) (0					
12. Was a chest CT scan taken within 90 days days after DISC?	s before to 60	⊔ Yes ⊔ i	Io □ Unknown If yes, were any of the chest CT scans a	phormal = Vos = No = Unknown		
days after Disc:			Date of first abnormal chest CT scans a			
			(mm/dd/yyyy)			
			For first abnormal chest CT scan, select	t all that apply;		
			☐ Air space density ☐ Air spa	ce opacity □ Consolidation □ Cavitary		
			lesions □ Granuloma □ Pulm	onary infiltrate □ Interstitial infiltrate		
				Report not available □ Other		
			(specify):	🗆 Unknown		
H. Vital Status						
1. Has the patient died?		□ No				
·		□ Voc. da	te of death//	(mm/dd/\\ana\)		
			of death	(IIIII/ du/ yyyy)		
		If yes, did death occur in hospital?   Yes  No  Unknown				
		, 55, 6	. acass. coomcopacoc			
		□ Unknown				
I. Antifungal Treatment						
1. Did the patient receive antifungal drugs do	uring the 90 days be	fore to 60	days after the DISC? ☐ Yes ☐ No	□ Unknown		
(If yes, please complete the table below for						
Select one of the following to complete each	row of the table:					
Annul statistic Dilinid	el.	(ELC)		(MEC)		
Amphotericin B lipid complex (ABLC) Fluconazole (			Micafungin			
Liposomal Amphotericin B (L-AmB) Amphotericin B coloidal dispersion (ABCD)	Flucytosine ( Ibrexafunc		Posaconazo Voriconazo	·		
Anidulafungin (ANF)	Isavuconazol			(OTH), specify:		
Caspofungin (CAS)	Itraconazole		Unknown o			
255210110111 (0.10)	3001142010	, <u>-</u> /	J.I.K.IOWITC			
Drug abbrev. First date given	Last date given		Indication Thera	apeutic Drug Monitoring (TDM)		

(mm/dd/yyyy)	(mm/dd/yyyy)		
//	//	□ Prophylaxis □ Treatment for <i>Blastomyces</i> □ Treatment for non- <i>Blastomyces</i> infection	□ Yes Date of earliest TDM: TDM level:  Date of second TDM: TDM level: □ No
//	//	□ Prophylaxis □ Treatment for Blastomyces □ Treatment for non- Blastomyces infection	□ Yes Date of earliest TDM: TDM level:  Date of second TDM: TDM level: □ No
//	//	□ Prophylaxis □ Treatment for <i>Blastomyces</i> □ Treatment for non- <i>Blastomyces</i> infection	□ Yes Date of earliest TDM: TDM level:  Date of second TDM: TDM level: □ No
//	//	□ Prophylaxis □ Treatment for <i>Blastomyces</i> □ Treatment for non- <i>Blastomyces</i> infection	□ Yes Date of earliest TDM: TDM level:  Date of second TDM: TDM level: □ No

## **PATIENT INTERVIEW**

J. Supplemental Patient Interview Form	
Note that the "you" in these questions refers t	to the patient.
1. Person interviewed	□ Patient □ Someone other than the patient, (specify relationship to patient):
2. Were you told that you had a positive lab result for blastomycosis before our call	☐ Yes  If yes, what type of healthcare setting told you? ☐ Emergency room ☐ Urgent care
today?	□ Primary care □ Hospital □ Pharmacy □ Public health official □ Other (specify): □ No  If no, were you told that you had a negative lab result for blastomycosis before our call today? □ Yes □ No □ Unsure
	☐ Unsure  If unsure, were you told that you had a negative lab result for blastomycosis before our call today?  ☐ Yes ☐ No ☐ Unsure
3. Is your home located in an urban, suburban, or rural area?	□ Urban □ Suburban □ Rural, wooded □ Rural, farmland □ Don't know
4. Do you live on or near a wetland?	□ Yes □ No □ Don't know

5. Do you live near a lake, river, stream, or pond?	☐ Yes  If yes, how far away? ☐ 0-300 ft ☐ >300 ft- <1 mile ☐ >1 mile  Name of body of water:		
6. In the 12 weeks before testing positive for blastomycosis or symptom onset, did you travel out of your home county or state?	□ Yes, specify city/state/dates:		
	□ No □ Don't know		
7. In the 12 weeks before testing positive for blastomycosis or symptom onset, which of the following outdoor activities did you participate in within an area known to have the fungus that causes blastomycosis (select all that apply)?	□ Hunting □ Fishing □ Swimming □ Boating □ Visiting a lake or river □ Camping □ Hiking □ Mountain biking □ Off-road/ATV □ Clearing/cutting wood □ Gathering natural products (berries, mushrooms, firewood) □ Gardening/landscaping If yes, exposure to: □ Mulch □ Topsoil □ Compost □ Leaf blowing □ Collecting/transporting yard waste □ Live/hike near a beaver dam □ Live/hike near an excavation site □ Exposed to rotten wood/vegetation □ Outdoor sports, specify □ Other outdoor activity, specify □ Other outdoor activity, specify □ None		
8. Has anyone else in the household been diagnosed with blastomycosis in the past 6 months?	□ Don't know □ Yes □ No □ Don't know		
9. Do you have any pets that have been diagnosed with blastomycosis in the past 6 months?	☐ Yes  If yes, what kind? ☐ Dog ☐ Cat ☐ Other  If yes, what breed? ☐ No ☐ Don't know		
10. In the 12 weeks before testing positive for blastomycosis, what kind of work did you do? If you did more than one type of job in the 12 weeks before you were tested, please tell us about each one:	□ Student □ Unemployed □ Retired □ Not applicable □ Unknown		
11. In the 12 weeks before testing positive for blastomycosis, what kind of industry did you work in? If you worked in more than one industry in the 12 weeks before you were tested, please tell us about each one:	Student  Unemployed  Retired  Not applicable  Unknown		
12 How often did you work travel or	□ Every day		

volunteer outdoors in the 12 weeks before	□ Most days			
testing positive for blastomycosis?	□ Some days			
	□ Rarely			
	□ Never			
	□ N/A			
	□ Don't know			
13. In the 12 weeks before testing positive for	□ Every day			
blastomycosis, how often did you wear a	□ Most days			
respirator like an N95 or KN95 or a mask at	□ Some days			
work?	□ Rarely			
	□ Never			
	□ N/A			
	□ Don't know			
14. Did you miss school or work because of	□ Yes, number of days			
blastomycosis?	□No			
	□ N/A			
	□ Don't know			
15. Had you ever heard of blastomycosis	□Yes			
before you were diagnosed or told of your	If yes, where did you hear about it? (check all that apply) □ Healthcare provider □ Internet			
positive result?	☐ Family member, friend, coworker ☐ Radio ☐ Television ☐ Other, specify			
	□ Don't know			
	□No			
	□ Don't know			
16. How do you think people get	□ From another person □ From animals □ From food □ From bug bites □ From water □ From the			
blastomycosis? (check all that apply)	environment   Other, specify   Don't know			
A 1 1949 1 4				

Additional comments:	